CORE--GASTROINTESTINAL AND HEPATOLOGY

该核心的目标是支持 关于骨髓移植的胃肠道和肝脏并发症的计划 移植，并开展相关的临床研究，我们的 患者 核心参与协议的设计，提供 肠和肝的诊断和评分的统一方法 并发症，确保用于研究目的的临床标本 获得并正确处理，并纵向跟踪患者 在整个过程中。 核心进行免疫组织化学， 用于研究目的的活组织检查标本的原位杂交和方法 用于生化分析的血液样品和生物流体。 临床 建议的研究活动包括：1）口腔 二丙酸倍氯米松治疗急性移植物抗宿主病 肠道疾病，然后是随机试验，如果有 安全性和有效性证据，2）熊去氧胆酸的随机试验 酸（一种比天然胆汁对细胞膜危害小的胆汁酸 酸）用于慢性GVHD患者和急性肝硬化患者。 对泼尼松龙治疗无反应的GVHD，3） 胆泥，和熊去氧胆酸的随机试验， 溶解移植后形成的胆囊泥，以及4） 丙型肝炎病毒流行率测定（聚合酶链法 反应）和抗-HCV，临床结果和长期后果， 移植患者的HCV感染

This objectives of this core are to support the research activities of the Program with regard to gastrointestinal and hepatic complications of marrow transplantation, and to carry out clinical research relevant to our patients. The core participates in the design of protocols, provides a uniform approach to the diagnosis and scoring of gut and liver complications, assures that clinical specimens used for research purposes are obtained and processed correctly, and follows patients longitudinally throughout their course. The core performs immunohistochemistry and in situ hybridization on biopsy specimens for research purposes, and processes blood samples and biological fluids for biochemical analysis. Clinical research activities proposed include: 1) a pilot study of oral beclomethasone dipropionate for the treatment of acute graft-versus-host disease of the intestine, followed by a randomized trial if there is evidence of safety and efficacy, 2) randomized trials of ursodeoxycholic acid (a bile acid which is less harmful to cell membranes than native bile acids) for patients with chronic GVHD and for patients with acute hepatic GVHD unresponsive to therapy with prednisolone, 3) biochemical analysis of gallbladder sludge, and a randomized trial of ursodeoxycholic acid for dissolution of gallbladder sludge which forms after transplantation, and 4) determination of the prevalence of hepatitis-C virus (by polymerase chain reaction) and anti-HCV, clinical outcomes, and long-term consequences of HCV infection in transplant patients.